UNSPSC 51144700: Stimulant or anorexiant amides

This classification denotes organic compounds containing the -CO-NH2 radical, substances called amides, that tend to increase behavioral alertness, agitation, or excitation, or otherwise, appetite depression, thus the term STIMULANT OR ANOREXIANT AMIDES.

UNSPSC 51144700 Stimulant or anorexiant amides is a Class code that in recent state and local procurement appears to cover pharmaceutical supply and drug management products broadly, though the code's nominal scope and the actual work being solicited show substantial misalignment. Recent opportunities tag this code for naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which fit the code's stated focus on stimulant or anorexiant amides. State and local solicitations under this code have come from health departments, multistate cooperative purchasing alliances, and county health authorities. Seminole County, Florida, and the Texas Health and Human Services Commission represent the issuing-body mix, though the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) procurement signals broader participation across state and local facilities in multiple states. The work ranges from purchase orders for naloxone and drug deactivation systems to exploratory market research on direct pharmaceutical contracting and competitive bidding for generic drug supply through authorized wholesalers.

The most recent activity appears concentrated in Florida and Texas, with cooperative purchasing spanning Minnesota and Oregon. Seminole County, Florida issued an Invitation for Bid (IFB 60459723LAS) due July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, inclusive of shipping costs and subject to a two-year initial term with one-year renewal option. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) in April 2026 to gather vendor capabilities for implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program outside traditional pharmacy benefit manager channels. MMCAP released a Request for Proposal (S1070000015802) in January 2026, due March 26, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and over-the-counter products through three authorized wholesalers, with awarded vendors taking effect July 1, 2026, and subject to a 3 percent administrative fee and performance penalties of $200 to $1,500 per violation. The coding mismatch suggests this code receives overly broad tagging in state procurement systems; the actual pharmaceutical and drug-management work present does not align with the stimulant or anorexiant amides descriptor.